Image credit: Kimimasa Mayama/​EPA/​Shutterstock
March 18, 2020 03:57 PM EDTUpdated 04:17 PM
R&D
China
Coronavirus

A Japan­ese flu drug gets up­beat re­views in Chi­na for blunt­ing the im­pact of Covid-19 — and that is bol­ster­ing Gilead­'s case for remde­sivir

John Carroll

Editor & Founder

We’re start­ing to get the first round of da­ta on drugs be­ing used to rein in the dev­as­tat­ing out­break of Covid-19 in Chi­na. And one …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

A service from the Financial Times